Strong Financial Position
SIGA maintains a robust cash balance of $172 million with no debt, providing flexibility and enabling the company to pursue opportunities and manage risks effectively.
Significant Product Revenue Growth
Product sales for the 9 months ended September 30, 2025, were approximately $86 million, outpacing the previous year's sales of $54 million for the same period.
Continued Government Engagement
Ongoing active engagement with the U.S. government regarding TPOXX development, manufacturing, and procurement, highlighting the importance of TPOXX as a critical medical countermeasure for smallpox.
International Sales Growth Potential
Multiple international sales expected in 2026 based on engagements and interest from key stakeholders across strategic markets.
Pipeline Advancements
Progress in the development of TPOXX for pediatric use and post-exposure prophylaxis program (PEP) for smallpox, with a targeted FDA submission for the PEP indication in 2026.